Current acute stroke trials and their potential impact on the therapeutic time window

Expert Review of Neurotherapeutics

Volumn 12, Issue 2, 2012, Pages 169-177

  Schellinger, Peter D ^a   Köhrmann, Martin ^b  

^a KLINIKUM MINDEN   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

citicoline; G CSF; hemodynamic augmentation; intra arterial thrombolysis; intravenous thrombolysis; near infrared laser therapy; NeuroFlo; rt PA; sphenopalatine ganglion stimulation; stroke MRI; thrombectomy devices

Indexed keywords

ABCIXIMAB; ALTEPLASE; CITICOLINE; DESMOTEPLASE; DISUFENTON SODIUM; ETHYLENEGLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID BIS(2 OCTYLOXYETHYL) ESTER; GRANULOCYTE COLONY STIMULATING FACTOR; PROUROKINASE; RECOMBINANT PLASMINOGEN ACTIVATOR; TIROFIBAN;

BARTHEL INDEX; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL PRACTICE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; DRUG SAFETY; ELECTROMAGNETIC RADIATION; FIBRINOLYTIC THERAPY; GLASGOW COMA SCALE; HEMODYNAMIC MONITORING; HEMODYNAMICS; HUMAN; INFRARED RADIATION; LOW LEVEL LASER THERAPY; MORTALITY; MULTIVARIATE ANALYSIS; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RANKIN SCALE; REVIEW; RISK; SCINTIGRAPHY; SPHENOPALATINE GANGLION BLOCK;

BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; FIBRINOLYTIC AGENTS; HUMANS; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84856609796     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.198     Document Type: Review

References (80)

1. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med. 359(13), 1317-1329 (2008).
2. Saver JL, Albers GW, Dunn B, Johnston KC, Fisher M. Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials. Stroke 40(7), 2594-2600 (2009).
3. Vahedi K, Hofmeijer J, Juettler E, et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol. 6(3), 215-222 (2007). (Pubitemid 46237760)
4. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363(9411), 768-774 (2004).
5. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 375(9727), 1695-1703 (2010).
6. Heuschmann PU, Berger K, Misselwitz B, et al. Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group. Stroke 34(5), 1106-1113 (2003).
7. Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 283(9), 1151-1158 (2000). (Pubitemid 30126603)
8. Wintermark M, Albers GW, Alexandrov AV, et al. Acute stroke imaging research roadmap. Stroke 29(5), e23-e30 (2008). (Pubitemid 351684949)
9. Schellinger PD. The evolving role of advanced MR imaging as a management tool for adult ischemic stroke: a Western-European perspective. Neuroimaging Clin. N. Am. 15(2), 245-258, ix (2005). (Pubitemid 41408490)
10. Schellinger PD, Thomalla G, Fiehler J, et al. MRI-based and CT-based thrombolytic therapy in acute stroke within and beyond established time windows: an analysis of 1210 patients. Stroke 38(10), 2640-2645 (2007). (Pubitemid 47493997)
11. Kohrmann M, Schellinger PD, Schwab S. The only evidence based neuroprotective therapy for acute ischemic stroke: thrombolysis. Best practice and research. Clin. Anaesthesiol. 24(4), 563-571 (2010).
12. Schellinger PD, Bryan RN, Caplan LR, et al. Evidence-based guideline: the role of diffusion and perfusion MRI for the diagnosis of acute ischemic stroke: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 75(2), 177-185 (2010).
13. Kidwell CS, Alger JR, Saver JL. Beyond mismatch: evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging. Stroke 34(11), 2729-2735 (2003). (Pubitemid 37392775)
14. Chalela JA, Kang DW, Luby M, et al. Early magnetic resonance imaging findings in patients receiving tissue plasminogen activator predict outcome: Insights into the pathophysiology of acute stroke in the thrombolysis era. Ann. Neurol. 55(1), 105-112 (2004). (Pubitemid 38067367)
15. Schellinger PD, Fiebach JB, Jansen O, et al. Stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia. Ann. Neurol. 49(4), 460-469 (2001).
16. Schlaug G, Benfield A, Baird AE, et al. The ischemic penumbra: operationally defined by diffusion and perfusion MRI. Neurology 53(7), 1528-1537 (1999). (Pubitemid 29491949)
17. Warach S. Tissue viability thresholds in acute stroke: the 4-factor model. Stroke 32(11), 2460-2461 (2001). (Pubitemid 33055288)
18. Campbell BC, Purushotham A, Christensen S, et al. The infarct core is well represented by the acute diffusion lesion: sustained reversal is infrequent. J. Cereb. Blood Flow Metab. 32(1), 50-56 (2012).
19. Schellinger PD, Fiebach JB, Hacke W. Imaging-based decision making in thrombolytic therapy for ischemic stroke: present status. Stroke 34(2), 575-583 (2003).
20. Lansberg MG, Lee J, Christensen S, et al. RAPID automated patient selection for reperfusion therapy: a pooled analysis of the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) and the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) study. Stroke 42(6), 1608-1614 (2011).
21. Campbell BC, Christensen S, Foster SJ, et al. Visual assessment of perfusion-diffusion mismatch is inadequate to select patients for thrombolysis. Cerebrovasc. Dis. 29(6), 592-596 (2010).
22. Latour LL, Kang DW, Ezzeddine MA, Chalela JA, Warach S. Early blood-brain barrier disruption in human focal brain ischemia. Ann. Neurol. 56(4), 468-477 (2004). (Pubitemid 39319336)
23. Fiehler J, Albers GW, Boulanger JM, et al. Bleeding risk analysis in stroke imaging before thrombolysis (BRASIL): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients. Stroke 38(10), 2738-2744 (2007). (Pubitemid 47494012)
24. Singer OC, Humpich MC, Fiehler J, et al. Risk for symptomatic intracerebral hemorrhage after thrombolysis assessed by diffusion-weighted magnetic resonance imaging. Ann. Neurol. 63(1), 52-60 (2008). (Pubitemid 351240551)
25. Schellinger PD, Jansen O, Fiebach JB, et al. Feasibility and practicality of MR imaging of stroke in the management of hyperacute cerebral ischemia. AJNR Am. J. Neuroradiol. 21(7), 1184-1189 (2000). (Pubitemid 30655650)
26. Buckley BT, Wainwright A, Meagher T, Briley D. Audit of a policy of magnetic resonance imaging with diffusion-weighted imaging as first-line neuroimaging for in-patients with clinically suspected acute stroke. Clin. Radiol. 58(3), 234-237 (2003). (Pubitemid 36335949)
27. Kohrmann M, Juttler E, Fiebach JB, et al. MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study. Lancet Neurol. 5(8), 661-667 (2006). (Pubitemid 44062409)
28. Fiebach JB, Schellinger PD, Jansen O, et al. CT and diffusion-weighted MR-Imaging in randomized order: DWI results in higher accuracy and lower interrater variability in the diagnosis of hyperacute ischemic stroke. Stroke 33(9), 2206-2210 (2002). (Pubitemid 35014631)
29. Chalela JA, Kidwell C, Nentwich L, et al. Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet 369(9558), 293-398 (2007).
30. Albers GW, Thijs VN, Wechsler L, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann. Neurol. 60(5), 508-517 (2006). (Pubitemid 44871793)
31. Thomalla G, Schwark C, Sobesky J, et al. Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in mri-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials. Stroke 37(3), 852-858 (2006). (Pubitemid 43731921)
32. Davis SM, Donnan GA, Parsons MW, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 7(4), 299-309 (2008).
33. Nagakane Y, Christensen S, Brekenfeld C, et al. EPITHET: positive result after reanalysis using baseline diffusion-weighted imaging/perfusion-weighted imaging co-registration. Stroke 42(1), 59-64 (2011).
34. Mlynash M, Lansberg MG, De Silva DA, et al. Refining the definition of the malignant profile: insights from the DEFUSE-EPITHET pooled data set. Stroke 42(5), 1270-1275 (2011).
35. Furlan AJ, Eyding D, Albers GW, et al. Dose escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 37(5), 1227-1231 (2006). (Pubitemid 43731867)
36. Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a Phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36(1), 66-73 (2005). (Pubitemid 40054177)
37. Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 8(2), 141-150 (2009).
38. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 282(21), 2003-2011 (1999).
39. Lewandowski CA, Frankel M, Tomsick TA, et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: emergency Management of Stroke (EMS) bridging trial. Stroke 30(12), 2598-2605 (1999).
40. The IMS 2 Investigators. The second interventional management of stroke study. Presented at: International Stroke Conference. Kissimmee, FL, USA, 16-18 February 2006.
41. The IMS II Trial Investigators. The Interventional Management of Stroke (IMS) II Study. Stroke 38(7), 2127-2135 (2007).
42. Smith WS. Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I. AJNR Am. J. Neuroradiol. 27(6), 1177-1182 (2006). (Pubitemid 44897621)
43. Smith WS, Sung G, Starkman S, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke. Results of the MERCI trial. Stroke 36(7), 1432-1440 (2005).
44. Nogueira RG, Liebeskind DS, Sung G, Duckwiler G, Smith WS. Predictors of good clinical outcomes, mortality, and successful revascularization in patients with acute ischemic stroke undergoing thrombectomy: pooled analysis of the Mechanical Embolus Removal in Cerebral Ischemia (MERCI) and Multi MERCI trials. Stroke 40(12), 3777-3783 (2009).
45. Struffert T, Kohrmann M, Engelhorn T, et al. Penumbra Stroke System as an 'add-on' for the treatment of large vessel occlusive disease following thrombolysis: first results. Eur. Radiol. 19(9), 2286-2293 (2009).
46. Bose A, Henkes H, Alfke K, et al. The Penumbra System: a mechanical device for the treatment of acute stroke due to thromboembolism. AJNR Am. J. Neuroradiol. 29(7), 1409-1413 (2008).
47. Miteff F, Faulder KC, Goh AC, Steinfort BS, Sue C, Harrington TJ. Mechanical thrombectomy with a self-expanding retrievable intracranial stent (Solitaire AB): experience in 26 patients with acute cerebral artery occlusion. AJNR Am. J. Neuroradiol. 32(6), 1078-1081 (2011).
48. Taschner CA, Treier M, Schumacher M, Berlis A, Weber J, Niesen W. Mechanical thrombectomy with the Penumbra recanalization device in acute ischemic stroke. J. Neuroradiol. 38(1), 47-52 (2011).
49. Baker WL, Colby JA, Tongbram V, et al. Neurothrombectomy devices for the treatment of acute ischemic stroke: state of the evidence. Ann. Intern. Med. 154(4), 243-252 (2011).
50. Benmira S, Banda ZK, Bhattacharya V. The start of a new era for stroke treatment: mechanical thrombectomy devices. Curr. Neurovasc. Res. 8(1), 75-85 (2011).
51. Rohde S, Haehnel S, Herweh C, et al. Mechanical thrombectomy in acute embolic stroke: preliminary results with the revive device. Stroke 42, 2954-2956 (2011).
52. Stampfl S, Hartmann M, Ringleb PA, Haehnel S, Bendszus M, Rohde S. Stent placement for flow restoration in acute ischemic stroke: a single-center experience with the solitaire stent system. AJNR Am. J. Neuroradiol. 32(7), 1245-1248 (2011).
53. Jovin TG, Liebeskind DS, Gupta R, et al. Imaging-based endovascular therapy for acute ischemic stroke due to proximal intracranial anterior circulation occlusion treated beyond 8 hours from time last seen well: retrospective multicenter analysis of 237 consecutive patients. Stroke 42(8), 2206-2211 (2011).
54. Nguyen TN, Babikian VL, Romero R, et al. Intra-arterial treatment methods in acute stroke therapy. Front. Neurol. 2, 9 (2011).
55. Gupta R, Tayal AH, Levy EI, et al. Intra-arterial thrombolysis or stent placement during endovascular treatment for acute ischemic stroke leads to the highest recanalization rate: results of a multicenter retrospective study. Neurosurgery 68(6), 1618-1623 (2011).
56. Mandava P, Kent TA. A method to determine stroke trial success using multidimensional pooled control functions. Stroke 40, 1803-1810 (2009).
57. Khatri P, Hill MD, Palesch YY, et al. Methodology of the Interventional Management of Stroke III Trial. Int. J. Stroke 3(2), 130-137 (2008). (Pubitemid 351566847)
58. Eckert B, Koch C, Thomalla G, et al. Aggressive therapy with intravenous abciximab and intra-arterial rt-PA and additional PTA/stenting improves clinical outcome in acute vertebrobasilar occlusion: combined local fibrinolysis and intravenous abciximab in acute vertebrobasilar stroke treatment (FAST): results of a multicenter study. Stroke 36(6), 1160-1165 (2005). (Pubitemid 40798732)
59. Schellinger PD, Hacke W. Recanalization devices should be restricted to clinical trials -Pro (kind of). Stroke 41(1), 191-193 (2010).
60. Coutts SB, Goyal M. When recanalization does not improve clinical outcomes. Stroke 40(8), 2661 (2009).
61. Diener HC, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke 39(6), 1751-1758 (2008).
62. Koziol JA, Feng AC. On the analysis and interpretation of outcome measures in stroke clinical trials: lessons from the SAINT I study of NXY-059 for acute ischemic stroke. Stroke 37(10), 2644-2647 (2006). (Pubitemid 44454693)
63. Ehrenreich H, Weissenborn K, Prange H, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 40(12), e647-e656 (2009).
64. Warach S, Hacke W, Hsu C, Luby M, Sullivan M, Noonan T. Effect of MaxiPost on ischemic lesions in patients with acute stroke: the POST-010 MRI Substudy. Stroke 33, 383 (2002).
65. Warach S, Pettigrew LC, Dashe JF, et al. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Ann. Neurol. 48(5), 713-722 (2000).
66. Warach S, Sabounjian LA. ECCO 2000 study of citicoline for treatment of acute ischemic stroke: effects on infarct volumes measured by MRI. Stroke 31(1), 42 (2000).
67. Clark WM. Efficacy of citicoline as an acute stroke treatment. Expert Opin. Pharmacother. 10(5), 839-846 (2009).
68. Schabitz WR, Laage R, Vogt G, et al. AXIS: a trial of intravenous granulocyte colony-stimulating factor in acute ischemic stroke. Stroke 41(11), 2545-2551 (2010).
69. Rosenberg G, Marshall LS, Caraco Y. The neuroprotective agent DP-b99 does not interact with s-warfarin in vivo despite significant CYP2C9 inhibition in vitro. Basic Clin. Pharm. Toxicol. 108(4), 289-292 (2011).
70. Diener HC, Schneider D, Lampl Y, Bornstein NM, Kozak A, Rosenberg G. DP-b99, a membrane-activated metal ion chelator, as neuroprotective therapy in ischemic stroke. Stroke 39(6), 1774-1778 (2008).
71. Rosenberg G, Bornstein N, Diener HC, Gorelick PB, Shuaib A, Lees K. The Membrane-Activated Chelator Stroke Intervention (MACSI) Trial of DP-b99 in acute ischemic stroke: a randomized, double-blind, placebo-controlled, multinational pivotal Phase III study. Int. J. Stroke 6(4), 362-367 (2011).
72. Shuaib A, Bornstein NM, Diener HC, et al. Partial aortic occlusion for cerebral perfusion augmentation: safety and efficacy of NeuroFlo in Acute Ischemic Stroke trial. Stroke 42(6), 1680-1690 (2011).
73. Liebeskind DS. Aortic occlusion for cerebral ischemia: from theory to practice. Curr. Cardiol. Rep. 10(1), 31-36 (2008).
74. Hammer M, Jovin T, Wahr JA, Heiss WD. Partial occlusion of the descending aorta increases cerebral blood flow in a nonstroke porcine model. Cerebrovasc. Dis. 28(4), 406-410 (2009).
75. Emery DJ, Schellinger PD, Selchen D, et al. Safety and feasibility of collateral blood flow augmentation after intravenous thrombolysis. Stroke 42(4), 1135-1137 (2011).
76. Khurana D, Kaul S, Bornstein NM. Implant for augmentation of cerebral blood flow trial 1: a pilot study evaluating the safety and effectiveness of the ischaemic stroke system for treatment of acute ischaemic stroke. Int. J. Stroke 4(6), 480-485 (2009).
77. Lampl Y, Zivin JA, Fisher M, et al. Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1). Stroke 38(6), 1843-1849 (2007). (Pubitemid 46847257)
78. Zivin JA, Albers GW, Bornstein N, et al. Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. Stroke 40(4), 1359-1364 (2009).
79. The IST3 Study Group. The Third International Stroke Trial (Thrombolysis). www.dcn.ed.ac.uk/ist3
80. The Internet Stroke Center. Welcome to the stroke trials registry. www.strokecenter.org/trials